Membranous Nephropathy clinical trials at University of California Health
2 research studies open to eligible people
Belimumab With Rituximab for Primary Membranous Nephropathy
open to eligible people ages 18-75
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous…
at UCLA UCSF
Nephrotic Syndrome Study Network
open to eligible people ages up to 80 years
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD)…
at UCLA UCSF
Our lead scientists for Membranous Nephropathy research studies include Sharon G. Adler Paul Brakeman, MD, PhD Raymond Hsu.
Last updated: